0001127602-14-003250.txt : 20140128 0001127602-14-003250.hdr.sgml : 20140128 20140128205835 ACCESSION NUMBER: 0001127602-14-003250 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140124 FILED AS OF DATE: 20140128 DATE AS OF CHANGE: 20140128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VIROPHARMA INC CENTRAL INDEX KEY: 0000946840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232789550 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 730 STOCKTON DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6104587300 MAIL ADDRESS: STREET 1: 730 STOCKTON DRIVE CITY: EXTON STATE: PA ZIP: 19341 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolf John Peter III CENTRAL INDEX KEY: 0001421915 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21699 FILM NUMBER: 14554637 MAIL ADDRESS: STREET 1: 397 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2014-01-24 0000946840 VIROPHARMA INC VPHM 0001421915 Wolf John Peter III 730 STOCKTON DRIVE EXTON PA 19341 1 VP, General Counsel Common Stock 2014-01-24 4 U 0 110768 50.00 D 0 D Common Stock 2014-01-24 4 A 0 48878 A 48878 D Common Stock 2014-01-24 4 D 0 48878 D 0 D Employee Stock Option (Right to Buy) 17.84 2014-01-24 4 D 0 18059 D 2012-01-05 2021-01-05 Common Stock 18059 0 D Employee Stock Option (Right to Buy) 17.98 2014-01-24 4 D 0 20131 D 2012-06-06 2021-06-06 Common Stock 20131 0 D Employee Stock Option (Right to Buy) 28.16 2014-01-24 4 D 0 27265 D 2013-01-05 2022-01-05 Common Stock 27265 0 D Employee Stock Option (Right to Buy) 20.07 2014-01-24 4 D 0 26793 D 2013-06-04 2022-06-04 Common Stock 26793 0 D Employee Stock Option (Right to Buy) 23.37 2014-01-24 4 D 0 34570 D 2014-01-03 2023-01-03 Common Stock 34570 0 D Employee Stock Option (Right to Buy) 27.79 2014-01-24 4 D 0 32516 D 2014-06-10 2023-06-10 Common Stock 32516 0 D Performance-based awards entitling the reporting person to shares of VPHM common stock upon the satisfaction of certain criteria were deemed satisfied in connection with the merger of ViroPharma Incorporated with and into Shire Pharmaceutical Holdings Ireland Limited, effective as of January 24, 2014 and canceled in exchange for an amount equal to $50 per share. The options vest in four equal annual installments beginning on the anniversary date from time of grant. This derivative security, regardless of whether otherwise previously vested, was canceled in connection with the merger of ViroPharma Incorporated with and into Shire Pharmaceutical Holdings Ireland Limited, effective as of January 24, 2014 in exchange for a cash payment representing the difference between the per-share exercise price of the stock option and $50. /s/ J. Peter Wolf 2014-01-28